OT mobile menu



ASCO 2015 Breast Cancer Symposium

Stay connected with the OncoTherapy Network as we highlight some of presentations taking place at the ASCO 2015 Breast Cancer Symposium, September 25-27 in San Francisco.


Image © Anita Ponne/ Shutterstock.com.
Image © Anita Ponne/ Shutterstock.com.
Image © Anita Ponne/ Shutterstock.com.
Image © Blamb / Shutterstock.com.
Image © Blamb / Shutterstock.com.
Image © Blamb / Shutterstock.com.
Nivolumab showed greater overall survival in patients with metastatic squamous NSCLC, - See more at: http://www.oncotherapynetwork.com/asco-2015/nivolumab-improves-response-...

Recent Content

Caveolin-1 (CAV1) appears to play an oncogenic role in breast cancer by fostering molecular hubs for signaling, and should be considered a potential target for therapeutic investigation, in particular in triple-negative disease.

The US Food and Drug Administration (FDA) today announced that it has granted accelerated approval for Merck’s anti-PD-1 agent pembrolizumab (Keytruda) for treating patients with refractory metastatic non-small cell lung cancer (NSCLC) tumors that express programmed cell death protein ligand 1 (PD-L1).

A special formula made of titanium and gold may be able to combat renal cell carcinoma in a whole new way. In a study published in the journal Chemical Science, researchers report this combination may be more be effective than cisplatin and also associated with little toxicity.

Multigene panels can detect significant pathogenic mutations in a proportion of breast cancer patients who have tested negative for BRCA1/2 gene mutations, according to a new study.

The PD-1 immune checkpoint inhibitor nivolumab (Opdivo) offers superior overall survival (OS) to docetaxel chemotherapy among patients with advanced nonsquamous non-small cell lung cancer (NSCLC) that has become refractory to first-line platinum-based doublet chemotherapy.

The US Food and Drug Administration (FDA) has approved nivolumab (Opdivo) in combination with ipilimumab (Yervoy) for treating patients with BRAF V600 wild-type unresectable or metastatic melanoma.

Nivolumab (Opdivo) may help improve overall survival and with fewer grade 3 or 4 adverse events compared to everolimus (Afinitor) in previously treated advanced renal cell carcinoma, according to new results from the CheckMate 025 phase III clinical trial presented at the 2015 European Cancer Congress in Vienna, Austria, September 25-29, 2015.

By clicking Accept, you agree to become a member of the UBM Medica Community.